ISPOR 2024 Student Research Highlight!
Introducing Zhen Zeng, one of our ISPOR 2024 Spotlight Poster Presenters! Join us on Tuesday , May 7th at 11:30 am-12:15 PM (EST) in the Poster Tour Area to learn more about this research!
Zhen Zeng, together with a skilled team from the University of Houston College of Pharmacy and the University of Arkansas, has advanced the understanding of personalized care in oncology through a pivotal cost-effectiveness study. The research focuses on the treatment of advanced nonsquamous non-small cell lung cancer, comparing Nivolumab, an innovative immunotherapy, with the traditional chemotherapy agent Docetaxel, while incorporating the implications of PD-L1 testing in the United States healthcare setting.
This study, employed a Markov model based on Checkmate-057 trial data, showing that Nivolumab is cost-effective, with an ICER of $55,322 per QALY compared to Docetaxel. This value is well below the accepted willingness-to-pay threshold of $150,000 per QALY. Further, stratification by PD-L1 expression levels demonstrated ICERs of $86,192 per QALY and $95,426 per QALY for the ≥1% and ≥10% PD-L1 test-based models, respectively. These findings provide compelling evidence for the economic viability of Nivolumab, supporting its adoption in targeted treatment strategies based on PD-L1 expression.